Overview
- Peer‑reviewed results in Med detail the first human safety evaluation of enteral ventilation using intrarectal perfluorodecalin.
- The study enrolled 27 healthy men in Japan who retained non‑oxygenated liquid doses up to 1,500 mL for 60 minutes under clinical monitoring.
- Twenty participants completed the full retention period, side effects were mild and dose‑related, and no serious adverse events or abnormal lab findings were reported.
- Efficacy was not assessed, and planned follow‑up trials will use oxygenated perfluorodecalin to quantify oxygen transfer and establish dosing and duration.
- The work builds on animal studies and is being advanced through EVA Therapeutics, with future trial timing dependent on fundraising.